The transport and cytotoxicity of
molybdenum-based drugs have been
explained with the concept of chemical transformation, a very important
idea in inorganic medicinal chemistry that is often overlooked in
the interpretation of the biological activity of metal-containing
systems. Two monomeric, [MoO2(L1)(MeOH)] (1) and [MoO2(L2)(EtOH)] (2), and two mixed-ligand dimeric MoVIO2 species,
[{MoO2(L1–2)}2(μ-4,4′-bipy)]
(3–4), were synthesized and characterized.
The structures of the solid complexes were solved through SC-XRD,
while their transformation in water was clarified by UV–vis,
ESI-MS, and DFT. In aqueous solution, 1–4 lead to the penta-coordinated [MoO2(L1–2)] active species after the release of the solvent molecule (1 and 2) or removal of the 4,4′-bipy bridge
(3 and 4). [MoO2(L1–2)] are stable in solution and react with neither serum bioligand
nor cellular reductants. The binding affinity of 1–4 toward HSA and DNA were evaluated through analytical and
computational methods and in both cases a non-covalent interaction
is expected. Furthermore, the in vitro cytotoxicity
of the complexes was also determined and flow cytometry analysis showed
the apoptotic death of the cancer cells. Interestingly, μ-4,4′-bipy
bridged complexes 3 and 4 were found to
be more active than monomeric 1 and 2, due
to the mixture of species generated, that is [MoO2(L1–2)] and the cytotoxic 4,4′-bipy released after
their dissociation. Since in the cytosol neither the reduction of
MoVI to MoV/IV takes place nor the production
of reactive oxygen species (ROS) through Fenton-like reactions of 1–4 with H2O2 occurs,
the mechanism of cytotoxicity should be attributable to the direct
interaction with DNA that happens with a minor-groove binding which
results in cell death through an apoptotic mechanism.